Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Warrants

<< Previous

Bullboard Posts

Next >>

Comment by pelabooston Aug 14, 2024 7:21pm

70 Views

Post# 36179553

RE:RE:RE:RE:Warrants

I think you may be right. There were almost 7.000.000 warrants in the July 2023 financing. One might assume the 3.5 were exercised. It does not really matter. Looking at these actions speaks to the sloppiness and questionable moves on many fronts in the past. Before the boo birds jump on this post, please note I am soon to be a cautious buyer.

I like Cantor on hand. I like the new guy. I certainly like the PDAC navigation.

We wait.

<< Previous

Bullboard Posts

Next >>

Dollar Tree CEO Rick Dreiling steps down as discount retailer struggles